Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EBT (2022 - 2026)

Core Laboratories filings provide 5 years of EBT readings, the most recent being -$1.0 million for Q1 2026.

  • On a quarterly basis, EBT fell 155.32% to -$1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $43.1 million, a 0.52% increase, with the full-year FY2025 number at $45.9 million, down 0.63% from a year prior.
  • EBT hit -$1.0 million in Q1 2026 for Core Laboratories, down from $13.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $18.3 million in Q3 2025 to a low of -$1.0 million in Q1 2026.
  • Median EBT over the past 5 years was $11.5 million (2023), compared with a mean of $10.3 million.
  • Biggest five-year swings in EBT: skyrocketed 75.18% in 2023 and later tumbled 155.32% in 2026.
  • Core Laboratories' EBT stood at $12.5 million in 2022, then dropped by 12.55% to $11.0 million in 2023, then grew by 5.31% to $11.5 million in 2024, then grew by 14.53% to $13.2 million in 2025, then crashed by 107.59% to -$1.0 million in 2026.
  • The last three reported values for EBT were -$1.0 million (Q1 2026), $13.2 million (Q4 2025), and $18.3 million (Q3 2025) per Business Quant data.